Ultrasound Guidance to Reduce Vascular and Bleeding Complications of Percutaneous Transfemoral Transcatheter Aortic Valve Replacement: A Propensity Score-Matched Comparison.


Journal

Journal of the American Heart Association
ISSN: 2047-9980
Titre abrégé: J Am Heart Assoc
Pays: England
ID NLM: 101580524

Informations de publication

Date de publication:
17 03 2020
Historique:
entrez: 17 3 2020
pubmed: 17 3 2020
medline: 10 3 2021
Statut: ppublish

Résumé

Background Ultrasound (US) guidance provides the unique opportunity to control the puncture zone of the artery during transfemoral transcatheter aortic valve replacement and may decrease major vascular complications (VC) and life-threatening or major bleeding complications. This study aimed to evaluate the clinical impact of US guidance using a propensity score-matched comparison. Methods and Results US guidance was implemented as the default approach for all transfemoral transcatheter aortic valve replacement cases in our institution in June 2013. We defined 3 groups of consecutive patients according to the method of puncture (fluoroscopic/US guidance) and the use of a transcatheter heart valve. Patients in the US-guided second-generation group (Sapien XT [Edwards Lifesciences, Irvine, CA], Corevalve [Medtronic, Dublin, Ireland]) were successfully 1:1 matched with patients in the fluoroscope-guided second-generation group (n=95) with propensity score matching. In a second analysis we described the consecutive patients of the US-guided third-generation group (Evolut-R [Medtronic], Sapien 3 [Edwards Lifesciences], n=308). All vascular and bleeding complications were reduced in the US-guided second-generation group compared with the fluoroscope-guided second-generation group: VC (16.8% versus 6.3%;

Identifiants

pubmed: 32172643
doi: 10.1161/JAHA.119.014916
pmc: PMC7335526
doi:

Banques de données

ClinicalTrials.gov
['NCT02628509']

Types de publication

Comparative Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e014916

Références

JACC Cardiovasc Interv. 2015 Dec 21;8(14):1797-806
pubmed: 26718510
JACC Cardiovasc Interv. 2010 Jul;3(7):751-8
pubmed: 20650437
Stat Med. 2009 Nov 10;28(25):3083-107
pubmed: 19757444
J Am Coll Cardiol. 2014 Dec 23;64(24):2605-2615
pubmed: 25524339
Crit Care. 2017 Aug 28;21(1):225
pubmed: 28844205
Multivariate Behav Res. 2011 May;46(3):399-424
pubmed: 21818162
J Am Coll Cardiol. 2017 Jul 4;70(1):42-55
pubmed: 28662806
J Am Coll Cardiol. 2007 Jul 3;50(1):69-76
pubmed: 17601548
JACC Cardiovasc Interv. 2019 Feb 25;12(4):370-372
pubmed: 30784642
J Am Coll Cardiol. 2012 Sep 18;60(12):1043-52
pubmed: 22883632
Crit Care Med. 2015 Nov;43(11):2479-502
pubmed: 26468699
N Engl J Med. 2016 Apr 28;374(17):1609-20
pubmed: 27040324
Lancet. 2016 May 28;387(10034):2218-25
pubmed: 27053442
J Invasive Cardiol. 2016 Aug;28(8):311-4
pubmed: 27466273
N Engl J Med. 2019 May 2;380(18):1695-1705
pubmed: 30883058
J Am Heart Assoc. 2020 Mar 17;9(6):e014916
pubmed: 32172643
JACC Cardiovasc Interv. 2017 Nov 27;10(22):2233-2241
pubmed: 29169493
J Invasive Cardiol. 2018 Jan;30(1):18-22
pubmed: 29035844
Nat Rev Cardiol. 2016 Nov;13(11):641-650
pubmed: 27558003
JACC Cardiovasc Interv. 2017 Nov 27;10(22):2269-2279
pubmed: 29169496
Am Heart J. 2012 Sep;164(3):402-9
pubmed: 22980308
Int J Cardiol. 2017 Oct 15;245:83-89
pubmed: 28760396
Stat Med. 2014 Mar 15;33(6):1057-69
pubmed: 24123228
J Am Coll Cardiol. 2012 Oct 9;60(15):1438-54
pubmed: 23036636
JACC Cardiovasc Interv. 2013 Jul;6(7):643-53
pubmed: 23866177
Catheter Cardiovasc Interv. 2016 Sep;88(3):407-23
pubmed: 27137680
Can J Cardiol. 2017 Jul;33(7):918-924
pubmed: 28579163
EuroIntervention. 2011 Jan;6(6):784-5
pubmed: 21205606

Auteurs

Flavien Vincent (F)

Cardiology Department of Interventional Cardiology for Coronary, Valves, and Structural Heart Diseases Institut Coeur Poumon CHU Lille Lille France.
Inserm U1011 Institut Pasteur de Lille EGID Lille France.
Université de Lille France.

Hugues Spillemaeker (H)

Cardiology Department of Interventional Cardiology for Coronary, Valves, and Structural Heart Diseases Institut Coeur Poumon CHU Lille Lille France.
Inserm U1011 Institut Pasteur de Lille EGID Lille France.
Université de Lille France.

Maéva Kyheng (M)

EA 2694-Santé Publique: Épidémiologie et Qualité des Soins CHU Lille University of Lille France.

Cassandre Belin-Vincent (C)

Cardiology Department of Interventional Cardiology for Coronary, Valves, and Structural Heart Diseases Institut Coeur Poumon CHU Lille Lille France.

Cédric Delhaye (C)

Cardiology Department of Interventional Cardiology for Coronary, Valves, and Structural Heart Diseases Institut Coeur Poumon CHU Lille Lille France.

Adeline Piérache (A)

EA 2694-Santé Publique: Épidémiologie et Qualité des Soins CHU Lille University of Lille France.

Tom Denimal (T)

Cardiology Department of Interventional Cardiology for Coronary, Valves, and Structural Heart Diseases Institut Coeur Poumon CHU Lille Lille France.
Inserm U1011 Institut Pasteur de Lille EGID Lille France.
Université de Lille France.

Basile Verdier (B)

Cardiology Department of Interventional Cardiology for Coronary, Valves, and Structural Heart Diseases Institut Coeur Poumon CHU Lille Lille France.
Inserm U1011 Institut Pasteur de Lille EGID Lille France.
Université de Lille France.

Nicolas Debry (N)

Cardiology Department of Interventional Cardiology for Coronary, Valves, and Structural Heart Diseases Institut Coeur Poumon CHU Lille Lille France.
Inserm U1011 Institut Pasteur de Lille EGID Lille France.
Université de Lille France.

Mouhamed Moussa (M)

Anesthésie et Réanimation Cardio-Vasculaire CHU Lille Lille France.
Inserm U1011 Institut Pasteur de Lille EGID Lille France.
Université de Lille France.

Guillaume Schurtz (G)

Cardiology Department of Interventional Cardiology for Coronary, Valves, and Structural Heart Diseases Institut Coeur Poumon CHU Lille Lille France.

Sina Porouchani (S)

Cardiology Department of Interventional Cardiology for Coronary, Valves, and Structural Heart Diseases Institut Coeur Poumon CHU Lille Lille France.

Alessandro Cosenza (A)

Cardiology Department of Interventional Cardiology for Coronary, Valves, and Structural Heart Diseases Institut Coeur Poumon CHU Lille Lille France.

Francis Juthier (F)

Chirurgie Cardiaque CHU Lille Lille France.
Inserm U1011 Institut Pasteur de Lille EGID Lille France.
Université de Lille France.

Thibault Pamart (T)

Cardiology Department of Interventional Cardiology for Coronary, Valves, and Structural Heart Diseases Institut Coeur Poumon CHU Lille Lille France.
Inserm U1011 Institut Pasteur de Lille EGID Lille France.
Université de Lille France.

Marjorie Richardson (M)

Cardiology Department of Interventional Cardiology for Coronary, Valves, and Structural Heart Diseases Institut Coeur Poumon CHU Lille Lille France.

Augustin Coisne (A)

Cardiology Department of Interventional Cardiology for Coronary, Valves, and Structural Heart Diseases Institut Coeur Poumon CHU Lille Lille France.
Inserm U1011 Institut Pasteur de Lille EGID Lille France.
Université de Lille France.

Adrien Hertault (A)

Chirurgie Vasculaire CHU Lille Lille France.

Jonathan Sobocinski (J)

Chirurgie Vasculaire CHU Lille Lille France.

Thomas Modine (T)

Chirurgie Cardiaque CHU Lille Lille France.
Inserm U1011 Institut Pasteur de Lille EGID Lille France.
Université de Lille France.

François Pontana (F)

Radiologie Cardiovasculaire CHU Lille Lille France.

Alain Duhamel (A)

EA 2694-Santé Publique: Épidémiologie et Qualité des Soins CHU Lille University of Lille France.

Julien Labreuche (J)

EA 2694-Santé Publique: Épidémiologie et Qualité des Soins CHU Lille University of Lille France.

Eric Van Belle (E)

Cardiology Department of Interventional Cardiology for Coronary, Valves, and Structural Heart Diseases Institut Coeur Poumon CHU Lille Lille France.
Inserm U1011 Institut Pasteur de Lille EGID Lille France.
Université de Lille France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH